Return to Home Incidence > Table

Incidence Rates Table

Data Options
Comparison Options

Incidence Rate Report by State

Kidney & Renal Pelvis (Late Stage^), 2018-2022

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by CI*Rank

State
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank
(95% Confidence Interval)
 sort by CI rank descending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late descending
Louisiana 7 6.7 (6.4, 7.0) 1 (1, 5) 374 28.6
Kentucky 7 6.4 (6.1, 6.7) 2 (1, 7) 361 29.5
Iowa 7 6.4 (6.0, 6.7) 3 (1, 9) 264 31.5
West Virginia 2 6.2 (5.8, 6.7) 4 (1, 13) 159 29.8
Oklahoma 2 6.2 (5.9, 6.6) 5 (1, 10) 295 29.3
Texas 7 6.2 (6.0, 6.3) 6 (2, 8) 1,893 29.4
Indiana 2 5.8 (5.5, 6.0) 7 (5, 18) 476 30.6
Missouri 2 5.8 (5.5, 6.0) 8 (5, 19) 453 28.9
North Dakota 2 5.6 (5.0, 6.4) 9 (1, 38) 51 29.0
New Mexico 7 5.6 (5.2, 6.0) 10 (4, 27) 152 33.8
Minnesota 2 5.6 (5.3, 5.9) 11 (6, 23) 398 31.1
Kansas 2 5.6 (5.2, 6.0) 12 (5, 26) 194 28.9
Nebraska 2 5.5 (5.1, 6.0) 13 (4, 29) 130 29.3
Rhode Island 2 5.5 (5.0, 6.1) 14 (3, 35) 80 33.2
Arkansas 2 5.5 (5.1, 5.8) 15 (6, 28) 207 25.1
Ohio 2 5.5 (5.3, 5.7) 16 (8, 23) 833 30.8
Wisconsin 2 5.5 (5.2, 5.7) 17 (7, 25) 424 29.4
Illinois 7 5.4 (5.3, 5.6) 18 (9, 24) 852 30.3
Mississippi 2 5.4 (5.0, 5.7) 19 (7, 29) 198 24.7
Tennessee 2 5.3 (5.1, 5.5) 20 (11, 28) 457 27.1
Wyoming 2 5.2 (4.5, 6.1) 21 (2, 46) 39 34.4
Georgia 7 5.2 (5.1, 5.4) 22 (13, 28) 644 29.2
Alaska 2 5.2 (4.4, 6.0) 23 (3, 47) 41 28.7
Maine 2 5.1 (4.7, 5.6) 24 (7, 43) 105 29.4
South Dakota 2 5.1 (4.5, 5.8) 25 (6, 46) 58 28.7
North Carolina 2 5.0 (4.9, 5.2) 26 (19, 32) 658 27.0
Idaho 7 5.0 (4.6, 5.5) 27 (10, 44) 111 27.9
Michigan 2 4.9 (4.8, 5.1) 28 (21, 35) 651 30.1
South Carolina 2 4.9 (4.7, 5.2) 29 (20, 39) 333 27.9
Vermont 2 4.8 (4.2, 5.6) 30 (7, 49) 44 32.6
Montana 2 4.8 (4.3, 5.3) 31 (12, 48) 70 28.9
Washington 1 4.8 (4.6, 5.0) 32 (24, 43) 438 31.0
California 7 4.7 (4.6, 4.8) 33 (29, 42) 2,113 31.3
New Jersey 7 4.7 (4.5, 4.8) 34 (27, 44) 546 29.8
New York 7 4.6 (4.5, 4.7) 35 (29, 44) 1,164 28.4
Oregon 2 4.6 (4.4, 4.9) 36 (25, 46) 255 29.3
Arizona 2 4.6 (4.4, 4.8) 37 (28, 46) 422 28.7
Pennsylvania 2 4.6 (4.4, 4.7) 38 (29, 45) 803 29.0
Alabama 2 4.6 (4.3, 4.8) 39 (27, 46) 294 24.9
Massachusetts 2 4.6 (4.4, 4.8) 40 (28, 46) 404 31.1
New Hampshire 2 4.6 (4.1, 5.0) 41 (22, 49) 89 27.8
Florida 2 4.5 (4.4, 4.6) 42 (32, 46) 1,403 28.6
Connecticut 7 4.4 (4.2, 4.7) 43 (29, 48) 212 29.3
Hawaii 7 4.4 (4.0, 4.8) 44 (26, 49) 86 34.3
Utah 7 4.4 (4.0, 4.7) 45 (28, 49) 130 27.4
Delaware 2 4.3 (3.8, 4.8) 46 (24, 50) 57 24.6
Virginia 2 4.1 (3.9, 4.3) 47 (43, 49) 431 25.8
Maryland 2 4.1 (3.9, 4.3) 48 (43, 50) 310 26.4
Colorado 2 4.0 (3.7, 4.2) 49 (44, 50) 261 27.1
Nevada 2 3.6 (3.3, 3.9) 50 (48, 51) 137 26.8
District of Columbia 2 2.9 (2.4, 3.6) 51 (50, 51) 20 24.4
Puerto Rico 2 2.0 (1.9, 2.2) N/A 100 24.1

Notes:
Created by statecancerprofiles.cancer.gov on 03/22/2026 5:07 pm.

State Cancer Registries may provide more current or more local data.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (SEER areas use 20 age groups and NPCR areas use 19 age groups). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage with Expanded Regional Codes (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.

⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. The rates used in CI*Rank are all age-adjusted to the 2000 US standard population using 19 age groups for SEER and NPCR areas. More information about methodology can be found on the CI*Rank website.

Source: SEER and NPCR data. For more specific information please see the table.

Data for United States does not include Puerto Rico.

CI*Rank data for Puerto Rico is not available.

Return to Top